About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
A new Gilead study shows that a single-tablet combo of HIV-fighting drugs could help patients who today take multiple drugs.
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis who were prescribed preexposure prophylaxis (PrEP), a preventative ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Amid steep cuts to US foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV-prevention ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback